1 / 26

DRUGS FOR BLOOD COAGULATION DISORDERS

DRUGS FOR BLOOD COAGULATION DISORDERS.

kwaddell
Télécharger la présentation

DRUGS FOR BLOOD COAGULATION DISORDERS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. DRUGS FOR BLOOD COAGULATION DISORDERS This study material is recommended specifically for practical courses from Pharmacology II for students of general medicine and stomatology. These brief notes could be used to prepare for the lesson and as a base for own notes during courses. Addititonal explanations and information are given in single lessons.

  2. Drugs for the blood coagulation disorders - +

  3. Anticoagulants • drugs inhibiting blood coagulation • monitoring of their efficacy usualy necessary - APTT orPT (INR) Direct - heparin and its derivatives Indirect - oral anticoagulants

  4. Direct anticoagulants Heparin MofA: speeds up antithrombine III interactions I: deep vein thrombosis, pulmonary embolia – therapy and prophylaxis.... CI:bleeding or risk of bleeding AE: bleeding – GIT, urinary tract, trombocytopenia Protamine sulphate = specific antagonist

  5. Direct anticoagulants Low molecular weight heparins (LMWH) • produced by standard heparin degradation MofA: block of Xa factor (coagulation early phase) Nadroparin, enoxaparin, dalteparin, parnaparin, reviparin, sulodexide • subcutaneous administration (exceptionally iv.)

  6. Direct anticoagulants - heparinoids • saccharide polysulphuric i.e. heparansulphate Direct anticoagulants Sulphonated pentasaccharide • fondaparinux, indraparinux

  7. Direct anticoagulants – thrombine inhibitors Antitrombine III Hirudin • lepirudin, desirudin, bivalirudin Melagatran/ximelagatran (pro-drug), dagibatran

  8. Indirect anticoagulants MofA: - vit. K competititve antagonists - induction of structurally incomplete coagulation factors • effective in vivo only • gradual onset of effect AE: - bleeding - rarely small intestine and skin necrosis I: thrombembolism prophyklaxis CI: - gastrointestinal ulcerations - thrombocytopenia - malign hypertension

  9. Indirect anticoagulants Warfarin – common drug-drug interactions = ↑ risk of bleeding Dicoumarol Ethyl biscoumacetate Fenprocoumon

  10. Fibrinolytics (thrombolytics) MofA: plasminogen activators (PA) I. generation II. generation non-selective→ their effect is linked with systemic fibrinolysis • streptokinase • urokinase selective firbrinolysis locally on the thrombus • t-PA • anistreplase • saruplase

  11. Fibrinolytics (thrombolytics) nonselective Streptokinase Urokinase

  12. Fibrinolytics (thrombolytics) selective t-PA • high binding capacity for fibrin • recombinant origin • alteplase • duteplase • reteplase • tenecteplase (TMK-tPA)

  13. Fibrinolytics (thrombolytics) selective Anistreplase ASPAC Fibrinolytics (thrombolytics) selective Saruplase (rscu–PA)

  14. Defibrinogating agents • snake venoms MofA: fibrinogen to fibrin conversion → consumption Ancrod (ancrodum) Batroxobin

  15. Antifybrinolytics MofA: block plasmin to fibrin binding AE: nausea CI: DIC • kyselina ε-aminocaproic acid (EACA) • tranexamic acid • p-aminomethylbenzoic acid (PAMBA) • aprotinin

  16. Antiaggregants (antiplatelet drugs) Modes of action 1. inhibition of thromboxane A2 production - COX inhibition 2. . inhibition of thromboxane A2 production by increase of cAMP levels in thrombocytes • phosphodiesterase inhibition • adenylate cyclase stimulation 3. inhibition of fibrinogen bounds formation • inhibition of ADP receptors • inhibition of IIb/IIIa receptors

  17. Antiaggregants Acetylsalicylic acid MofA: ireversible COX inhibition • dose dependant effect,usualy administered chronicaly once daily in the dose of 50-100 mg I: AIM, nonstableAP AIM prevention ischemicstroke AE: app. 20 % of patients 10-20% are ASA resistant

  18. Antiaggregants - NSAIDs - reversible COX inhibition Sulfinpyrazone Indobufen Picotamide

  19. Antiaggregants– pentoxyphylline Antiaggregants– dipyridamole

  20. Antiaggregants– tienopyridiny ticlopidin a clopidogrel Ticlopidine Clopidogrel Prasugrel – 3.generation

  21. Antiagregační (protidestičkové) látky TXA2 antagonists sulotroban, ditazole, dextransulphate IIb/IIIa Rc antagonists trigramine – from snake venom eptifibatide, tirofiban, lamifiban amidoximes abciximab

  22. Hemostatics Local: With vasoconstringent activity etamsylate ornipressin terlipressin desmopressin Without vasoconstringent activity gelatine gelatine sponge collagen Systemic: frozen plasma, human fibrinogen, thrombine, coagulation factors

  23. Therapy of anemia and hematopoietic factors

  24. Anemy therapy– with regard to cause Pharmacotherapy: Iron deficiency – ferrous sulphate p.o. - malabsorption Fe-dextrane orFe- sorbitol intramusculary Folic acid deficiency → oral supplementation Vitamin B12 deficiency (cobalamine) → hydroxycobalamine intramusculary

  25. Hematopoietic growth factors • controls proliferation, maturation and differentiation of blood cels Erythropoietin– released from kidneys, hypoxia or massive blood loss induce relase Thrombopoietin CSF– regulates myeloid white cell line proliferation, produced during infections

  26. Colony stimulating factors G-CSF – granulocytes CSF →filgrastim, lenograstim GM-CSF – granulocytes-macrophages CSF →molgrasmostim Use: - to reduce neutropenia during cytotoxic therapy - oncology– to stimulate release of progenitor cells to peripheral blood for collection and subsequent therapeutic use after chemotherapy - AIDS

More Related